Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for ALKEM
Revenue projections for ALKEM

Alkem Laboratories Limited's revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.

Financial Ratios:

currentRatio 2.486000
forwardPE 29.911581
debtToEquity 17.056000
earningsGrowth 0.111000
revenueGrowth 0.172000
grossMargins 0.624410
operatingMargins 0.206740
trailingEps 197.360000
forwardEps 191.313860

ALKEM's current ratio is 2.486, signaling that the company has sufficient cash reserves and current assets to cover its short-term debt obligations. This suggests financial stability, as ALKEM should not face any issues meeting its short-term liabilities with available resources.
ALKEM's Forward PE is at a healthy level, indicating that the stock price is well-positioned relative to its earnings. With the stock not being overvalued, there remains room for future growth, suggesting a balanced opportunity for investors seeking potential upside.
Alkem Laboratories Limited's low Debt-to-Equity ratio demonstrates that the company is not over-leveraged. This means it maintains a healthy balance between debt and equity, lowering financial risk and contributing to overall financial stability, which could attract risk-averse investors.
Positive earnings and revenue growth for Alkem Laboratories Limited suggest that the company is positioned for business expansion. The company's strong financial performance indicates sustained growth, as increasing sales and profits fuel its future success.
ALKEM's positive gross and operating margins highlight its profitability and operational efficiency. These strong margins demonstrate the company's ability to control costs while generating substantial revenue, contributing to a healthy financial performance.
ALKEM's lower forward EPS compared to trailing EPS suggests the company will likely experience reduced earnings in the current year. This may signal a less optimistic financial outlook.

Price projections:

Price projections for ALKEM
Price projections for ALKEM

Over time, price projections for ALKEM have risen steadily, pointing to growing optimism among analysts about the company's future. This upward trend suggests a positive outlook for ALKEM's continued growth.

Recommendation changes over time:

Recommendations trend for ALKEM
Recommendations trend for ALKEM


ALKEM has been receiving a buy bias from analysts, indicating confidence in its investment potential. This could drive more investors to view ALKEM as a reliable choice for their money, offering a promising avenue for future growth and financial gains.